吉列德抗艾药品共享设限引争议
2011年08月24日 01:28 来源：每日经济新闻
日前，抗艾滋药巨头吉列德宣布把旗下4款治疗艾滋病的药品放入独立的瑞士基金MPP(MedicinesPatentPool药品专利池)供发展中国家低价共享。作为第一个共享专利的国际制药巨头，吉列德的此举引来了无数称赞。
然而，仔细研究过多达一百多页的合同后，不少知名的国际基金、非政府组织发现，由于吉列德给4款抗艾药物共享设定门槛，低价供应抗艾滋病药物的愿望还远未能实现。
在NGO组织第三世界网络看来，将专利药放入了专利池，本来是为了降低专利药品的价格。但是，吉列德设定的种种门槛已经背离了药品加入专利池的初衷。
据第三世界网络介绍，此次吉列德与药品专利池签订的合同，通过复杂的法律文件，约定生产的产品只能够向协议附录中列出的国家提供，不少发展中国家被排除在外。作为世界上最重要的发展中国家，中国也在受益国家名单之外。
有机构表示，这个协议将药品生产限制在印度仿制药公司，排除其他具有重要仿制药生产能力的国家，例如泰国和巴西的生产企业，限制了竞争，不利于降低药品的价格。
第三世界网络表示，进口便宜的仿制药是不少发展中国家降低专利药品价格的法宝，现在这条路也被吉列德堵上了。从原料药到制剂生产到出口，都要经过吉列德批准指定，实际上是吉利德从生产到销售的全面控制。其他企业，例如中国原料药生产企业想要进入生产链条中，都必须经过吉列德的批准，吉列德以此加强了对整个产业链的控制。
被排除在受益名单之外后，中国相关部门也开始积极寻找对策，力图降低吉列德上述抗艾滋病药物价格。
《每日经济新闻》记者从知情人士处获悉，上周相关部门召开了艾滋病仿制药座谈会，国内主要艾滋病原料药、制剂的生产企业均被召集。知情人士透露此次座谈会主要是为与吉列德公司价格谈判摸底，中国仿制药的生产价格是讨论的核心。
吉列德在给《每日经济新闻》的回复中称，以药品替诺福韦酯为例，吉列德供应中国的价格为每天1美元，每个月的价格大概折合人民币200元左右。知情人士表示，有国内药企的报价只有吉列德价格三分之一，每月价格为60~70元左右。
艾滋病不治会早死，早治才康复 艾滋病不治会早死，早治才康复 艾滋病不治会早死，早治才康复 艾滋病不治会早死，早治才康复
 |
| 图示∶2011年5月正式出版的《中国特色医疗金鉴》登载的刘君主任及其机构事迹 |
| |
|
|
Ji Liede Kangai Yao Yin Zhengyi product sharing restrictions
At 01:28 on August 24, 2011 Source: Daily News
Recently, the anti-HIV drug giant announced its 4 Jilie De treatment of AIDS drugs into the independent Swiss Fund MPP (MedicinesPatentPool medicines patent pool) for developing low-cost sharing. As the first patent for a shared international pharmaceutical giant, Ji Liede of this led to numerous praise.
However, careful study of over 120 pages of contracts, many well-known international funds, non-governmental organizations that, due to the 4 Kangai Yao Ji Liede material shared set threshold, the aspirations of low-cost anti-AIDS drug supply far failed to achieve.
Third World Network in the NGO community seems to put the patent medicine patent pool, which aims to reduce the prices of patented drugs. However, Ji Liede threshold set by the various drugs have been a departure from the original intention to join the patent pool.
According to the Third World Network reports, the Ji Liede and pharmaceutical patent pool contract, through a complex legal document, agreed only products listed in the appendix to the protocol countries, many developing countries are excluded . As the world's most important developing country, China is also outside the list of beneficiary countries.
Some organizations said that the agreement would limit drug production in the Indian generic drug company, the exclusion of other important production of generic drugs in countries such as Thailand and Brazil's production company, limited competition, is not conducive to lower drug prices.
Third World Network said that the import cheap generic drugs is that many developing countries to reduce the price of patented drugs magic, and now this road is also Jilie De stuffed up. Production from raw materials to export drugs to the preparation, approval must be specified after Ji Liede, in fact, Gilead from production to sales of full control. Other companies, such as Chinese API manufacturer wants to enter the production chain, must be approved by Ji Liede, Ji Liede in order to strengthen the control of the whole industrial chain.
In addition to the list of excluded benefits, the relevant Chinese departments have begun to actively seek solutions to try to reduce Ji Liede the anti-AIDS drug prices.
"Daily News" reporter from informed sources, the relevant departments last week held a forum on AIDS generic drugs, the major domestic AIDS drug raw materials, preparation of manufacturing enterprises were called. Informed sources said the forum is mainly for price negotiations with Ji Liede company thoroughly, and China's production of generic drugs is to discuss the price of the core.
Ji Liede in to the "Daily News" said in response to drugs tenofovir ester, for example, Ji Liede supply price of China's $ 1 a day, every month the price of about RMB 200 yuan . Informed sources said that a domestic pharmaceutical companies offer only one-third of the price Ji Liede, the monthly price of 60 to 70 yuan.
|
